Skip to main content
Premium Trial:

Request an Annual Quote

Merged Bruker Reports Increased Q3 Revenues

NEW YORK, Nov. 5, (GenomeWeb News) - Bruker BioSciences today reported revenues of $63 million for the third quarter ending Sept. 30, up over the $57 million for the year-ago quarter.

 

The company results reflect a merger-related charge of $6.4 million for the July 1 merger of Bruker Daltonics and Bruker AXS, and results from prior periods are historical combined reports of the two previously separate companies.

 

The company had a third-quarter net loss of $14.7 million, compared to a net income of $1.2 million for the year-ago quarter.

 

Bruker reported research and development costs of $9.6 million for the quarter, compared to $7.7 million for the same quarter last year. The firm reported cash, and short-term investments of $78 million for the quarter, as compared to $100 million for the year ago period.

 

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.